GeneMatrix Inc (109820) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of GeneMatrix Inc stock KRW 956, price KRW 1,305, that is 26.7% below the price, quality 62 out of 100. Rating: overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 1,305 KRW – 16,800 KRW · fair‑value band 685.88 KRW – 1,271 KRW · the 1,305 KRW price screens above the 956.37 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow GeneMatrix in your weekly email
Every Wednesday you see whether GeneMatrix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics.
Show moreShow less
The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment.
It also provides biochemical diagnostics, such as special chemistry and general chemistry, that includes semi and full auto analyer, and calibrators and controls. The company was founded in 2000 and is headquartered in Seongnam-si, South Korea.
Stock analysis
GeneMatrix Inc (109820) currently trades at 1,305 KRW, while our model-based Fair Value estimate is 956.37 KRW, 27% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 974.67 KRW per share, and 0 of the 7 models we run sit above the 1,305 KRW price.
Bear case: the Asset-Based group reads lowest at 520.98 KRW, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: 685.88 KRW (bear) to 1,271 KRW (bull), the price of 1,305 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
GeneMatrix Inc reported revenue of 10.6B KRW in FY2025 versus 12.1B KRW in FY2021, a compound −3.2%/yr. Reported net income was −1.8B KRW in FY2025.
Key figures
Market cap 26.1B KRW (≈ $19.3M) Micro · P/S ratio 5.92 · EPS (TTM) −104.85 KRW · Net margin −44.3% · Return on equity −15.6% · Return on assets (EBIT) −4.9% (5-year average) · Operating margin −45.8% · Revenue (TTM) 4.7B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 49% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −27%, 109820 screens richer than that median.
Fair Value models
Bear685.88 KRWFair Value 956.37 KRWBull1,271 KRW
Price 1,305 KRW · Downside -26.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.7%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.8% (2020) → −6.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +11.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside−26.7% · Above median
Profitability
Return on assets−6.7% · Bottom 25%
Net margin (12 months)−44.3% · Bottom 25%
Operating margin (12 months)−45.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−5.4% · Bottom 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/B1.49× · Cheaper than median
P/S (12 months)5.52× · Pricier than median
Price / free cash flow (fiscal year)21.3× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 39
PAST (return on equity)0· sector 15
HEALTH (low debt)100· sector 95
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "GeneMatrix Inc Fair Value". https://www.fairvalue-calculator.com/stock/109820
Frequently asked questions
Is GeneMatrix Inc (109820) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 956.37 KRW versus a price of 1,305 KRW, about 27% lower (overvalued).
What is the fair value of 109820?
Our model-based fair value for GeneMatrix Inc is 956.37 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 1,305 KRW.
What is the quality score of 109820?
GeneMatrix Inc has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GeneMatrix Inc (109820)?
Our model-based price target is the fair value of 956.37 KRW (as of Nov 3, 2026) from 7 valuation models. Cautious scenario 685.88 KRW, optimistic scenario 1,271 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the GeneMatrix Inc stock forecast for 2026?
Our models put fair value at 956.37 KRW, about 27% lower versus a price of 1,305 KRW (overvalued). Cautious scenario 685.88 KRW, optimistic scenario 1,271 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of GeneMatrix Inc (109820)?
GeneMatrix Inc reported trailing-twelve-month revenue of about 4.7B KRW (latest available figure, as of Nov 3, 2026).
What growth is priced into GeneMatrix Inc (109820)?
For today's price to be fair in a discounted-cash-flow model, GeneMatrix Inc would have to grow free cash flow by +13.3 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -7.7 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 109820 use?
Our models discount GeneMatrix Inc at 10.3 %: a base by market capitalisation (nano), damped by beta 1.04, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GeneMatrix Inc that is +13.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has GeneMatrix Inc (109820) delivered so far?
Over the past 5 years revenue at GeneMatrix Inc grew -7.7 % a year. The price currently implies free-cash-flow growth of +13.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GeneMatrix Inc (109820) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into GeneMatrix Inc (+13.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GeneMatrix Inc (109820)?
The free-cash-flow yield on the price is 4.71 %: that much free cash flow GeneMatrix Inc produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GeneMatrix Inc (109820)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GeneMatrix Inc it is 956.37 KRW per share (as of Nov 3, 2026), against a price of 1,305 KRW. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is GeneMatrix Inc stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 109820 trades above its calculated fair value: price 1,305 KRW, fair value 956.37 KRW, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 109820?
No. The price is what the market pays today (1,305 KRW); the fair value is what the company's own numbers justify (956.37 KRW). For GeneMatrix Inc the two are 348.63 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is GeneMatrix Inc worth?
The market values GeneMatrix Inc at about 26.1B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 1,305 KRW; our models calculate a fair value of 956.37 KRW per share.
What do the bullish and bearish scenarios say about 109820?
Our models span a range for GeneMatrix Inc: cautious scenario 685.88 KRW, base 956.37 KRW, optimistic 1,271 KRW per share (as of Nov 3, 2026, price 1,305 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of GeneMatrix Inc (109820)?
Balance-sheet figures for GeneMatrix Inc (as of Nov 3, 2026): return on equity −15.6%. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 109820 from its 52-week high?
GeneMatrix Inc trades at 1,305 KRW, about 49% below its 52-week high of 2,545 KRW and at the low of 1,305 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 956.37 KRW is for.
Which stocks are comparable to GeneMatrix Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GeneMatrix Inc stock attractive at the current price?
The data as of Nov 3, 2026: price 1,305 KRW, calculated fair value 956.37 KRW (−27%), Quality Score 62/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 109820 calculated?
We run GeneMatrix Inc through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 956.37 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. GeneMatrix Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GeneMatrix Inc (109820)?
The closing price on Nov 9, 2026 was 1,305 KRW. Our model-based fair value is 956.37 KRW, about 27% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GeneMatrix Inc right now?
The price sits above even our optimistic bull case (1,271 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (685.88 KRW to 1,271 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of GeneMatrix Inc
How large is the market capitalisation of GeneMatrix Inc (109820)?
The market capitalisation of GeneMatrix Inc is 26.1B KRW (≈ $19.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GeneMatrix Inc (109820)?
The price-to-sales ratio of GeneMatrix Inc is 5.92 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GeneMatrix Inc (109820)?
Earnings per share at GeneMatrix Inc are −104.85 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of GeneMatrix Inc (109820)?
The net margin of GeneMatrix Inc is −44.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GeneMatrix Inc (109820)?
The return on equity (ROE) of GeneMatrix Inc is −15.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GeneMatrix Inc (109820)?
On an EBIT basis the return on assets of GeneMatrix Inc is −4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GeneMatrix Inc (109820)?
The operating margin of GeneMatrix Inc is −45.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GeneMatrix Inc (109820)?
Revenue at GeneMatrix Inc is growing −5.4% versus a year earlier (3y avg −1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does GeneMatrix Inc (109820) carry?
The net debt of GeneMatrix Inc is 1.3B KRW (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch GeneMatrix Inc in the live analysis
One click puts GeneMatrix Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026